Trial
NCT04926324
A Safety Study Adding Niraparib and Dostarlimab to Radiation Therapy for Rectal Cancers
Phase ITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
University of Iowa
Collaborators
GlaxoSmithKline
Condition
Rectal Neoplasms
Intervention
Niraparib
Why stopped
Toxicity in phase 1
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-06-29